Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRIUMPH-2 (obesity + T2D)

TRIUMPH-2 (obesity + T2D)

Retatrutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
t2d
Official title
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2023-07 → 2026-06
Participants
1152
Duration
80 weeks
Registry
NCT05929079

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
retatrutide 4 mgt2d80—−12.7 % vs −4.0 %
Δ −8.7 pp
−11.9 % vs −5.1 %
Δ −6.8 pp
−1.4 vs −0.53.0 vs 5.010.3 vs 21.514.0 vs 8.06.0 vs 4.08.0 vs 8.0−5.0 vs −2.7verified
retatrutide 9 mgt2d80—−19.1 % vs −4.0 %
Δ −15.1 pp
−16.8 % vs −5.1 %
Δ −11.7 pp
−1.5 vs −0.511.0 vs 5.019.4 vs 21.521.0 vs 8.010.0 vs 4.09.0 vs 8.0−7.4 vs −2.7verified
retatrutide 12 mgt2d80—−20.8 % vs −4.0 %
Δ −16.8 pp
−18.8 % vs −5.1 %
Δ −13.7 pp
−1.4 vs −0.57.0 vs 5.013.9 vs 21.528.0 vs 8.016.0 vs 4.09.0 vs 8.0−9.7 vs −2.7verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (27)
  • retatrutide 4 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
    –12·7% (SE 0·6) in the 4 mg group
  • retatrutide 4 mg · weight_tp · Results, paragraph 4; Table 2
    was −11·9% (SE 0·6; −12·9 kg [0·6]) with retatrutide 4 mg
  • retatrutide 4 mg · ae_dc · Results, paragraph 2; Figure 1
    Ten (3%) participants in the retatrutide 4 mg group
  • retatrutide 4 mg · disc_any · Figure 1
    30 discontinued study drug
  • retatrutide 4 mg · nausea · Results, safety paragraph; Table 3
    nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
  • retatrutide 4 mg · vomiting · Results, safety paragraph; Table 3
    in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
  • retatrutide 4 mg · sae · Results, safety paragraph; Table 3
    Serious adverse events were reported by 24 (8%) in the retatrutide 4 mg group
  • retatrutide 4 mg · hba1c · Results, paragraph 6; Table 2
    The mean change from baseline to week 80 in HbA1c was −1·38% (SE 0·06) with retatrutide 4 mg
  • retatrutide 4 mg · sbp · Results, paragraph 8; Table 2
    −5·0 mm Hg [SE 0·7] with 4 mg
  • retatrutide 9 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
    –19·1% (0·6) in the 9 mg group
  • retatrutide 9 mg · weight_tp · Results, paragraph 4; Table 2
    −16·8% (0·7; −18·3 kg [0·8]) with retatrutide 9 mg
  • retatrutide 9 mg · ae_dc · Results, paragraph 2; Figure 1
    31 (11%) in the retatrutide 9 mg group
  • retatrutide 9 mg · disc_any · Figure 1
    55 discontinued study drug
  • retatrutide 9 mg · nausea · Results, safety paragraph; Table 3
    nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
  • retatrutide 9 mg · vomiting · Results, safety paragraph; Table 3
    in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
  • retatrutide 9 mg · sae · Results, safety paragraph; Table 3
    25 (9%) in the retatrutide 9 mg group
  • retatrutide 9 mg · hba1c · Results, paragraph 6; Table 2
    −1·50% (0·07) with retatrutide 9 mg
  • retatrutide 9 mg · sbp · Results, paragraph 8; Table 2
    –7·4 mm Hg [0·8] with 9 mg
  • retatrutide 12 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
    and –20·8% (0·6) in the 12 mg group
  • retatrutide 12 mg · weight_tp · Results, paragraph 4; Table 2
    −18·8% (0·7; −20·7 kg [0·8]) with retatrutide 12 mg
  • retatrutide 12 mg · ae_dc · Results, paragraph 2; Figure 1
    21 (7%) in the retatrutide 12 mg group
  • retatrutide 12 mg · disc_any · Figure 1
    40 discontinued study drug
  • retatrutide 12 mg · nausea · Results, safety paragraph; Table 3
    nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
  • retatrutide 12 mg · vomiting · Results, safety paragraph; Table 3
    in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
  • retatrutide 12 mg · sae · Results, safety paragraph; Table 3
    27 (9%) in the retatrutide 12 mg group
  • retatrutide 12 mg · hba1c · Results, paragraph 6; Table 2
    −1·45% (0·07) with retatrutide 12 mg
  • retatrutide 12 mg · sbp · Results, paragraph 8; Table 2
    −9·7 mm Hg [0·8] with 12 mg

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRIUMPH-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.